ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

SAIC Begins Transition Of Frederick Operations From Incumbent PRI

March 17, 1995

In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End

November 26, 1999

Why Shouldn’t Scientific Issues Be Discussed In Open Meetings? Editorial

November 10, 1989

FDA Proposes To Drop Specific Requirements For Reprint Distribution On Off-Label Uses.

February 22, 2008

In Brief: Garb Raps “Hostility Of Executive Branch”; Hew Considers Allowing Grants For Industry

April 25, 1980

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995